CBS 2019
CBSMD教育中心
中 文

经皮左心耳封堵

Abstract

Recommended Article

Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial Anticoagulation in Concomitant Chronic Kidney Disease and Atrial Fibrillation: JACC Review Topic of the Week Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial Left atrial appendage occlusion in atrial fibrillation patients with previous intracranial bleeding: A national multicenter study Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial Percutaneous Left Atrial Appendage Closure for Stroke Prophylaxis in Patients With Atrial Fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) Trial Subclinical and Device-Detected Atrial Fibrillation: Pondering the Knowledge Gap: A Scientific Statement From the American Heart Association Early Rhythm-Control Therapy in Patients with Atrial Fibrillation

ConsensusVolume 76, Issue 5, August 2020

JOURNAL:J Am Coll Cardiol. Article Link

2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Solution Set Oversight Committee

GF Tomaselli, KW Mahaffey, A Cuker et al. Keywords: ACC Expert Consensus Decision Pathway; apixaban; atrial fibrillation; betrixaban; dabigatran; edoxaban; rivaroxaban; venous thromboembolism; warfarin

Full Text PDF